CORDIS · 223477 · FP7
ABC Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use of medicines in Europe
Coordinator: UNIVERSYTET MEDYCZNY W LODZI. (PL)
Medication non-compliance is highly prevalent across all medical conditions, and represents a major barrier for realising the benefits of evidence-based therapies. The aim of the project is to produce evidence-based policy recommendations for improving patient compliance and subsequent better use of medicines by Europeans. Lack of consensus in the terminology used in this field impedes benchmarking of compliance-enhancing interventions. Therefore the first stage of the project will be to build a pan-European consensus on terminology and taxonomy of non-compliance. Effective interventions in t…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €2.2M toward a total project budget of €2.9M — a funding rate of 77%, with the remainder covered by the consortium partners. The project runs over approximately 3.5 years from 2009-01-01 to 2012-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from PL
see all →- UASEEDs — SEEDS OF BRAVERY: supporting Ukraine’s tech start-up scene and bringing it closer to the EU101104445 · HORIZON · €20.0M
- P4Health — Centre of Excellence for Precise Phenotyping and BioDataBanking101136375 · HORIZON · €15.0M
- Astrocent Plus — Astrocent Plus -- Particle Astrophysics Science and Technology Centre101137080 · HORIZON · €15.0M
- TRIO-VI CoE — Translational Research and Innovation in Ophthalmology Vision - Centre of Excellence101136570 · HORIZON · €15.0M
- QuantERA III — QUANTERA III RIA: COFUND IN QUANTUM TECHNOLOGIES101212998 · HORIZON · €15.0M
- QuantERA II — QuantERA II ERA-NET Cofund in Quantum Technologies101017733 · H2020 · €15.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-FP funding scheme.
- What is the EU contribution?
- The European Commission contributes €2.2M toward a total project budget of €2.9M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by UNIVERSYTET MEDYCZNY W LODZI. (PL).
- What is the project timeline?
- The project runs from 2009-01-01 to 2012-06-30 — approximately 3.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 223477.